OKA was found to increase levels of phosphorylated tau (Figure 2B) and GSK-3β by blocking PP2A activity [63], causing the accumulation of NFTs, resulting in AD-like neuropathology [49]. The gene discussed is MAPT; the disease is Alzheimer disease.